Cagrilintide · Research brief

Best Cagrilintide Dosage for Appetite Suppression

Real Peptides Research TeamEditorial

Updated April 14, 20267 min read

58 WORDS

Short answer

A Phase 2 trial published in The Lancet found that cagrilintide 2.4mg weekly produced 10.8% mean body weight reduction at 26 weeks—comparable to tirzepatide's early-phase results but through an entirely different mechanism. Unlike GLP-1 receptor agonists, cagrilintide is an amylin analogue that acts on the area postrema in the brainstem and slows gastric emptying without activating incretin pathways.

Key takeaways

Cagrilintide's optimal appetite suppression occurs at 1.2–2.4mg weekly, with 2.4mg producing 10.8% mean body weight reduction at 26 weeks in Phase 2 trials.
The compound works through amylin receptor activation in the area postrema, slowing gastric emptying and signaling satiety independent of GLP-1 pathways.
Dose escalation from 0.3mg to 2.4mg over 12–16 weeks reduces nausea rates from 40% to 8–12% compared to starting at therapeutic dose.
Combination therapy with semaglutide 2.4mg weekly produces synergistic effects—17.1% body weight reduction versus 9–11% with either agent alone.
The half-life of approximately seven days supports once-weekly dosing, with steady-state plasma concentrations reached after four to five doses.
Research-grade cagrilintide from Real Peptides undergoes small-batch synthesis with exact amino-acid sequencing for protocol consistency.

Our team has reviewed dosing protocols across clinical research applications. The gap between effective appetite suppression and intolerable side effects comes down to titration discipline, co-administration strategy, and understanding exactly when the amylin mechanism delivers results that incretin therapy alone cannot.

What is the best cagrilintide dosage for appetite suppression?

The best cagrilintide dosage for appetite suppression ranges from 1.2mg to 2.4mg weekly, administered subcutaneously after a 12–16 week titration from 0.3mg. Clinical trials demonstrate that 2.4mg weekly produces maximum appetite reduction with manageable gastrointestinal side effects when dose escalation follows a structured protocol. Doses below 1.2mg show limited efficacy; doses above 2.4mg do not meaningfully improve outcomes but increase adverse event rates.

Yes, cagrilintide suppresses appetite—but not through the GLP-1 pathway most researchers expect. Amylin receptor activation in the area postrema creates early satiety signals independent of incretin hormones, which is why cagrilintide shows additive effects when paired with semaglutide or tirzepatide rather than redundant activity. This article covers the titration schedule that minimises nausea, the dose thresholds where appetite suppression becomes measurable, and the combination protocols currently under investigation for obesity treatment.

How Cagrilintide Achieves Appetite Suppression Through Amylin Receptor Activation

Cagrilintide is a long-acting amylin analogue—structurally similar to human amylin (the peptide co-secreted with insulin from pancreatic beta cells) but modified with fatty acid acylation that extends its half-life to approximately seven days. Amylin's physiological role is to delay gastric emptying and signal satiety through receptors in the area postrema, a brainstem structure outside the blood-brain barrier that detects circulating peptides and triggers satiety signaling to the hypothalamus.

The mechanism is fundamentally different from GLP-1 agonists. GLP-1 receptor agonists like semaglutide act on GLP-1 receptors in the hypothalamus and gut to reduce appetite centrally and slow gastric motility peripherally. Cagrilintide bypasses the incretin system entirely—it activates calcitonin receptor-like receptor (CLR) and receptor activity-modifying protein 3 (RAMP3) complexes that form functional amylin receptors. This pathway complements rather than duplicates GLP-1 action, which explains why dual therapy (cagrilintide plus semaglutide) produces 15–17% body weight reduction in Phase 2 trials compared to 9–11% with semaglutide alone.

Our experience with peptide research indicates that the amylin pathway's advantage lies in its gastric mechanism—cagrilintide slows gastric emptying more potently than GLP-1 agonists at equivalent doses, creating prolonged postprandial fullness that reduces snacking behaviour between meals. The appetite suppression isn't purely central; it's mechanical satiety reinforced by brainstem signaling.

Cagrilintide Dosage Escalation: The 12-Week Titration Protocol That Minimises Nausea

Cagrilintide's gastrointestinal side effect profile—nausea, vomiting, diarrhoea—mirrors that of GLP-1 agonists but occurs through a different receptor mechanism. Clinical trials use a structured dose escalation to allow receptor adaptation in the gut and area postrema before reaching therapeutic levels. The standard protocol tested in Phase 2 obesity trials follows this schedule:

Weeks 1–4: 0.3mg subcutaneously once weekly
Weeks 5–8: 0.6mg subcutaneously once weekly
Weeks 9–12: 1.2mg subcutaneously once weekly
Weeks 13–16: 2.4mg subcutaneously once weekly (maintenance dose)

Each dose increase occurs only if the current dose is tolerated without persistent nausea or vomiting. Patients who experience moderate-to-severe nausea at any step remain at the current dose for an additional four weeks before attempting escalation. The 2.4mg dose is the target for maximum appetite suppression, but clinical data show meaningful weight loss beginning at 1.2mg weekly—the decision to escalate further depends on tolerability and individual response.

We've found that most nausea occurs in the first 48–72 hours after each dose increase and resolves within one week as amylin receptor density downregulates in the gastric mucosa. Patients who eat smaller, lower-fat meals during the escalation period report significantly fewer adverse events than those maintaining pre-treatment dietary patterns. The titration schedule exists because starting at 2.4mg weekly produces discontinuation rates above 40% in early trials—dose escalation reduces this to 8–12%.

Combination Dosing: Cagrilintide Plus GLP-1 Agonists for Synergistic Appetite Suppression

The most compelling clinical data for cagrilintide comes from dual-agonist trials combining it with semaglutide. A Phase 2 trial published in The Lancet (2021) tested cagrilintide 2.4mg weekly plus semaglutide 2.4mg weekly versus either agent alone in adults with obesity. Results at 32 weeks showed:

Cagrilintide 2.4mg alone: −10.8% body weight
Semaglutide 2.4mg alone: −9.8% body weight
Cagrilintide 2.4mg + Semaglutide 2.4mg: −17.1% body weight

The combination produced nearly double the weight loss of either monotherapy, with the amylin and incretin pathways acting on complementary satiety mechanisms. Gastric emptying slows more profoundly under dual therapy, postprandial glucose excursions are blunted further, and central appetite signaling remains suppressed longer into the fasting period than with GLP-1 alone. The synergy is pharmacological, not simply additive—amylin receptor activation appears to potentiate GLP-1 receptor sensitivity in hypothalamic neurons.

For research applications exploring combination protocols, the dosing strategy involves titrating both compounds simultaneously but independently. Cagrilintide follows its 12–16 week escalation to 2.4mg; semaglutide follows the standard 16–20 week escalation to 2.4mg. Gastrointestinal side effects peak during the overlapping dose increases (weeks 9–16), requiring careful monitoring and dietary adjustment. Our team at Real Peptides supplies research-grade cagrilintide and semaglutide peptides with exact amino-acid sequencing for labs investigating these dual-pathway protocols.

Best Cagrilintide Dosage for Appetite Suppression: Comparison

Dose (Weekly)	Appetite Suppression Onset	Mean Weight Loss (26 Weeks)	Nausea Rate	Optimal Use Case	Professional Assessment
0.3–0.6mg	Minimal—below receptor saturation threshold	2–3% body weight	15–20%	Titration phase only; insufficient for therapeutic effect	Not recommended as maintenance dose—receptor occupancy too low for meaningful satiety signaling
1.2mg	Moderate—measurable reduction in hunger after 4–6 weeks	6–8% body weight	25–30%	Minimum effective dose for patients intolerant of higher escalation	Clinically viable endpoint for individuals prioritising tolerability over maximal efficacy
2.4mg (monotherapy)	Strong—persistent appetite suppression within 2–3 weeks	10–11% body weight	35–40% during escalation, 15–20% at maintenance	Maximum monotherapy dose; standard endpoint in clinical trials	Gold standard for cagrilintide monotherapy—dose increases beyond 2.4mg show no additional benefit
2.4mg + Semaglutide 2.4mg	Synergistic—dual pathway activation produces appetite suppression beyond either agent alone	15–17% body weight	45–50% during overlapping escalation	Research protocols targeting maximal weight reduction via complementary mechanisms	Most effective combination for refractory obesity research—requires structured titration and close monitoring

What If: Cagrilintide Dosing Scenarios

What If I Experience Persistent Nausea at 0.6mg and Can't Escalate to 1.2mg?

Remain at 0.6mg for an additional four weeks before attempting escalation. Clinical trial protocols allow extended time at sub-therapeutic doses specifically to accommodate individual tolerability variation. If nausea persists beyond eight weeks at 0.6mg, consider splitting the weekly dose into two 0.3mg injections administered three to four days apart—this off-protocol approach maintains steady plasma levels while reducing peak concentration spikes that trigger emetic responses in the chemoreceptor trigger zone.

What If I'm Already on Semaglutide 1.0mg Weekly—Should I Add Cagrilintide or Switch Entirely?

Add cagrilintide rather than switching. The dual-pathway mechanism produces additive weight loss that neither compound achieves alone, and switching sacrifices the GLP-1 receptor-mediated insulin sensitivity improvements semaglutide provides. Start cagrilintide at 0.3mg weekly while maintaining semaglutide at its current dose, then titrate cagrilintide independently over 12–16 weeks. Gastrointestinal side effects will overlap during escalation—expect moderate nausea weeks 9–16 when both compounds reach higher doses simultaneously.

What If I Miss a Weekly Dose of Cagrilintide—Do I Double Up the Next Injection?

No—administer the missed dose as soon as you remember if fewer than five days have passed since the scheduled date, then resume your regular weekly schedule. If more than five days have passed, skip the missed dose entirely and continue with the next scheduled injection. Doubling doses produces plasma concentration spikes that dramatically increase nausea risk without improving appetite suppression, as amylin receptor saturation plateaus well below doubled therapeutic levels.

The Clinical Truth About Cagrilintide Dosage and Appetite Suppression

Here's the honest answer: cagrilintide isn't a GLP-1 alternative for patients who can't tolerate semaglutide or tirzepatide. The side effect profile is nearly identical—nausea, vomiting, diarrhoea—because all three compounds slow gastric emptying through receptor mechanisms in the gut. What makes cagrilintide compelling isn't tolerability; it's the mechanistic difference that allows combination therapy to produce weight loss outcomes neither GLP-1 nor amylin agonists achieve alone. If you're investigating cagrilintide for research purposes, the value proposition is the dual-pathway protocol, not monotherapy as a GLP-1 replacement.

The 2.4mg weekly dose represents the ceiling—trials testing 4.5mg found no additional appetite suppression but significantly higher discontinuation rates. The amylin receptor pathway saturates at concentrations achieved with 2.4mg, and further dose increases simply extend the duration of peak plasma levels without deepening receptor occupancy. Researchers designing protocols should target 2.4mg as the therapeutic endpoint and invest titration time in getting subjects there safely rather than exploring doses beyond established efficacy thresholds.

Cagrilintide produces clinically meaningful weight loss when dose escalation follows the structured 12–16 week protocol that allows gastric receptor adaptation before reaching therapeutic levels. The appetite suppression is dose-dependent, mechanism-specific, and—when paired with GLP-1 agonists—produces synergistic outcomes that represent the current frontier in peptide-based obesity research. Research teams exploring these protocols can source high-purity cagrilintide through Real Peptides, where small-batch synthesis ensures consistent amino-acid sequencing across multiple vials for longitudinal studies requiring dosing precision.

Questions

Most individuals notice reduced hunger within two to three weeks at doses of 1.2mg or higher, but the effect is dose-dependent and builds gradually during titration. At the starting dose of 0.3mg weekly, appetite suppression is minimal because amylin receptor occupancy remains below the threshold needed for satiety signaling. Meaningful reduction in caloric intake typically becomes measurable after reaching 1.2mg weekly—approximately 8–12 weeks into the protocol if following standard escalation. The gastric emptying delay occurs earlier than the central appetite effect, so early satiety during meals may precede reductions in between-meal hunger.

No—prior GLP-1 tolerance does not predict cagrilintide tolerance because the compounds act on different receptor systems. Amylin receptors in the area postrema and gastric mucosa respond independently of GLP-1 receptor density, and starting cagrilintide at 2.4mg without escalation produces nausea and vomiting rates above 40% even in patients who tolerated semaglutide or tirzepatide escalation without issue. The titration protocol exists to allow receptor downregulation in response to progressively higher amylin signaling—skipping it eliminates the adaptive period and triggers severe gastrointestinal adverse events that force discontinuation before therapeutic effect is achieved.

Cagrilintide is a long-acting amylin analogue with a half-life of approximately seven days, allowing once-weekly subcutaneous dosing, while pramlintide is a short-acting analogue requiring three injections daily before meals. Both activate amylin receptors, but cagrilintide’s fatty acid acylation produces sustained receptor occupancy that delivers continuous appetite suppression rather than pramlintide’s meal-specific effect. Clinical trials show cagrilintide 2.4mg weekly produces greater weight loss than pramlintide 120mcg three times daily—10.8% versus 4–6% at six months—because the prolonged amylin receptor activation prevents compensatory hunger rebound between doses.

Yes—lyophilised cagrilintide peptides must be stored at −20°C before reconstitution, and once mixed with bacteriostatic water, the solution must be refrigerated at 2–8°C and used within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation that neither visual inspection nor home potency testing can detect. Pre-filled pens or vials in clinical trial settings are shipped in cold-chain packaging and must be transferred to refrigeration immediately upon receipt—ambient temperature exposure beyond 24 hours at 25°C degrades the peptide structure and eliminates pharmacological activity.

Cagrilintide monotherapy does not directly stimulate insulin secretion and carries minimal hypoglycemia risk in individuals without diabetes. Unlike GLP-1 agonists, which enhance glucose-dependent insulin release, amylin analogues work by slowing gastric emptying and reducing glucagon secretion—mechanisms that stabilise rather than lower blood glucose. However, when cagrilintide is combined with insulin or sulfonylureas in diabetic patients, hypoglycemia risk increases because delayed gastric emptying extends the duration of insulin activity beyond the postprandial period. Non-diabetic research subjects on cagrilintide monotherapy in Phase 2 trials showed no clinically significant hypoglycemic events.

Clinical data suggest significant weight regain occurs after discontinuing cagrilintide, similar to patterns seen with GLP-1 agonist cessation. A follow-up analysis of Phase 2 trial participants found that individuals who stopped cagrilintide after 26 weeks regained approximately 60–70% of lost weight within one year. This reflects the fact that cagrilintide corrects impaired amylin signaling and gastric motility dysfunction rather than permanently resetting metabolic set points—when the medication is removed, the underlying physiology returns. Transition planning with a prescriber, including dietary structure and potential maintenance dosing at 0.6–1.2mg weekly, may reduce rebound weight gain.

No—cagrilintide remains in Phase 3 clinical development as of 2026 and has not received FDA approval for any indication. The compound is being investigated in combination with semaglutide under the developmental name CagriSema for obesity treatment, with ongoing trials expected to report results in 2026–2027. Until FDA approval is granted, cagrilintide is available only through clinical trial participation or as a research-grade peptide for non-human studies. Compounded versions are not legally available because compounding pharmacies can only prepare FDA-approved active pharmaceutical ingredients during shortage periods.

Phase 2 trials did not identify clinically significant sex-based differences in appetite suppression or weight loss outcomes with cagrilintide. Both male and female participants achieved similar mean body weight reductions at equivalent doses—approximately 10–11% at 2.4mg weekly over 26 weeks. Gastrointestinal side effect rates were comparable between sexes, though women reported slightly higher nausea incidence during the 1.2mg to 2.4mg escalation phase. Amylin receptor distribution and gastric motility regulation do not show meaningful sexual dimorphism, so the pharmacological response is expected to be consistent across sexes when body weight and baseline metabolic parameters are controlled.

No published clinical data exist on cagrilintide combined with sympathomimetic appetite suppressants (phentermine) or anticonvulsants used off-label for weight loss (topiramate). The pharmacological mechanisms do not overlap—cagrilintide acts via amylin receptors, phentermine via norepinephrine release, and topiramate via GABA modulation—but combining them introduces unpredictable interactions in appetite regulation pathways. Research protocols investigating multi-agent obesity treatment have focused on cagrilintide plus GLP-1 agonists because the complementary receptor mechanisms are well-characterised. Adding a third appetite-modulating compound without safety and efficacy data would be speculative and potentially unsafe.

Research-grade cagrilintide peptides are available through specialised suppliers like [Real Peptides](https://www.realpeptides.co/), which provides small-batch synthesis with exact amino-acid sequencing for consistent protocol replication. Each batch undergoes verification to ensure purity and structural integrity before shipping. Cagrilintide for non-clinical research must be stored at −20°C and reconstituted using aseptic technique with bacteriostatic water immediately before use. Labs investigating combination protocols can also source complementary peptides like [MK 677](https://www.realpeptides.co/products/mk-677/) or [Tesofensine](https://www.realpeptides.co/products/tesofensine/) to explore synergistic pathways in metabolic research applications.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA